CME
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
August 18, 2023
Host: Jeffrey S. Weber, MD, PhD
Host: Ryan Sullivan, MD
Host: Omid Hamid, MD
Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. Howev
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!